mTOR inhibitors and autosomal dominant polycystic kidney disease

New England Journal of Medicine

Volumn 364, Issue 3, 2011, Pages 286-289

  Grantham, Jared J ^a   Bennett, William M ^b   Perrone, Ronald D ^c  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b LEGACY GOOD SAMARITAN HOSPITAL   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; RAPAMYCIN;

AUTOSOMAL DOMINANT DISORDER; CHRONIC KIDNEY DISEASE; DISEASE COURSE; DISEASE MARKER; GLOMERULUS FILTRATION RATE; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; KIDNEY SIZE; LETTER; PRIORITY JOURNAL;

EID: 78751606994     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1010845     Document Type: Letter

References (6)

1. Walz G, Budde K, Mannaa M, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010;363:830-40. [Errata, N Engl J Med 2010;363:1190, 1977.]
2. Serra AL, Poster D, Kistler AD, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010;363:820-9.
3. Torres VE, Boletta A, Chapman A, et al. Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Soc Nephrol 2010;5:1312-29.
4. Perico N, Antiga L, Caroli A, et al. Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol 2010;21:1031-40.
5. Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. N Engl J Med 2006;354:2122-30.
6. Bae KT, Grantham JJ. Imaging for the prognosis of autosomal dominant polycystic kidney disease. Nat Rev Nephrol 2010;6:96-106.